Stem cell yield and transplantation in transplant-eligible newly diagnosed multiple myeloma patients receiving daratumumab + bortezomib/thalidomide/dexamethasone in the phase 3 CASSIOPEIA study

著者: Cyrille Hulin, Fritz Offner, Philippe Moreau, Murielle Roussel, Karim Belhadj, Lotfi Benboubker, Denis Caillot, Thierry Façon, Laurent Garderet, Frédérique Kuhnowski, Anne‐Marie Stoppa, Brigitte Kolb, Mourad Tiab, Kon‐Siong G. Jie, Matthijs Westerman, Jérôme Lambert, Lixia Pei, Véronique Vanquickelberghe, Carla de Boer, Jessica Vermeulen, Tobias Kampfenkel, Pieter Sonneveld, Niels W.C.J. van de Donk - Haematologica 2021 被引用: 52

Stem cell yield and transplantation in transplant-eligible newly diagnosed multiple myeloma patients receiving daratumumab plus bortezomib